Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIDE: Psilocybin vs Personalized Neuromodulation for Treatment-Resistant Depression
2024-519844-34-03Phase 2Authorised
- Sponsor
- Università degli Studi Gabriele d'Annunzio Chieti e Pescara
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in treatment-resistant depression (TRD) comparing Psilocybin (PEX010) with Placebo/control (2 arms). Primary endpoint: Clinical response (MADRS). Planned start Jul 2025; status: authorised.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2024-519844-34-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519844-34-03.